Univo IRB has announced the launch of its Canadian research ethics board (REB) review services, aimed at supporting clinical trials in North America.
This offering is intended to maintain the highest standards of ethical integrity and regulatory compliance.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The introduction of the review services will enhance the capabilities of Univo IRB. It aims to offer a more simplified approval process for researchers and sponsors, potentially leading to more efficient clinical trial operations.
The offering includes features such as accelerated review timelines, comprehensive feedback and continuous oversight throughout the trial life-cycle.
This approach is expected to reduce delays and facilitate the smooth progression of clinical trials, without compromising on ethical standards.
The next-generation institutional review board (IRB), Univo IRB (previously Principal IRB), focuses on the ethical review of Phase I-IV pharmaceutical, biologic, device, behavioural, and psycho-social research.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis board provides a service-first methodology, expert solutions driven by market-leading study technology, and agile study methodologies.
Univo IRB is accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
With guidance from senior advisers and more than 60 years of combined industry experience, Univo IRB is well-equipped to navigate studies to approval while prioritising patient rights and welfare.
Univo IRB executive chair Cyrus Gill said: “Under the guidance of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, this diverse group brings together experts in ethics, law, and scientific disciplines, alongside respected community ambassadors.
“By assembling this distinguished board for Canada and adhering to both Canadian and international regulatory requirements, we reaffirm our dedication to advancing research outside the US responsibly and ethically while unifying clinical research with our passion for patient protection, education, and advocacy.”
